Investment platform takes a direct role in the success of six companies ahead of the JP Morgan Healthcare Conference.

AngelMD announced that its Catalyst LP I Fund will invest in six companies selected from a pool of over 150 applicants. The funding announcement comes in conjunction with the company's Alpha Conference, on January 5th and 6th in Napa, California. Conference attendees and AngelMD members will be given the opportunity to invest in the startups after their presentations.

“This is a unique opportunity for startups. Not only do they get an investment from our Catalyst Fund, but they get a syndicate of investors from our network at the same time.” said Charles Emley Jr., Managing Partner, Catalyst I, LP.

The winning companies are:

Beta Cat Pharmaceuticals
Noninvasix
Otomagnetics
Pharmajet
Seal Rock Therapeutics
Sensulin

“We are always impressed with the high quality of startups that register on AngelMD. When we host events such as Alpha, we are able to draw from a very deep pool of strong companies. This process has not only created efficient new capital investment and visibility for the startups, it ensures our conference attendees and members are getting access to high quality, curated deal flow,” said Jens Francis, Chief Investment Officer, AngelMD

About AngelMD

AngelMD is an investment and networking platform connecting innovative medical startups, physicians, investors, and industry partners. Leading physicians from all over the US have joined AngelMD to help source, evaluate and advise companies in biotechnology, medical device, and healthcare technology. For more information visit http://www.angelmd.co.